Form 8-K

C. R. BARD, INC.

(Registrant)

Date: June 18, 2015

/s/ Richard C. Rosenzweig

Richard C. Rosenzweig

Vice President, Law and Assistant Secretary

Lutonix DCB freedom from TLR rate of 82% is consistent

with published stent freedom from TLR rates

“Stent Like TLR” Continued

at 24 Months

86.6

77.8

75.3

80.3

79.4

84.0

100

Zilver PTX

Resilient

(Lifestent)

Durability II

(Everflex)

Stroll

(SMART)

Viastar

(Viabahn w/

propaten)

Superb

(Supera)

LEVANT 2 DCB Freedom from TLR rate = 82%

*TLR is defined as Target Lesion Revascularization. This was a secondary endpoint in the LEVANT 2 trial. Reported stent TLR rates are from Kaplan-Meier analyses at 24 months, not pre-

specified. LEVANT 2 PTA arm 79%. These data are not from head-to-head clinical studies. Comparing the results of different clinical trials can be misleading, as each study may have varying

patient profiles, protocol structures and other criteria that may affect reported outcomes. This presentation of data is provided for background and general education purposes only.

INDICATIONS FOR USE: The LUTONIX

035 Drug Coated Balloon PTA catheter is indicated for percutaneous transluminal angioplasty, after

pre-dilatation, of de novo or restenotic lesions up to 150mm in length in native superficial femoral or popliteal arteries with reference

vessel diameters of 4-6mm.

CONTRAINDICATIONS : The LUTONIX

Catheter is contraindicated for use in: 1) Patients who cannot receive recommended anti-platelet

and/or anticoagulant therapy. 2) Women who are breastfeeding, pregnant or are intending to become pregnant or men intending to

father children. It is unknown whether paclitaxel will be excreted in human milk and there is a potential for adverse reaction in

nursing infants from paclitaxel exposure. 3) Patients judged to have a lesion that prevents complete inflation of an angioplasty

balloon or proper placement of the delivery system.

WARNINGS: Contents supplied STERILE using ethylene oxide (EO) process. Do not use if sterile barrier is damaged or opened prior to

intended use. Do not use if product damage is evident. The LUTONIX

Catheter is for use in one patient only; do not reuse in another

patient, reprocess or resterilize. Risks of reuse in another patient, reprocessing, or resterilization include: Compromising the

structural integrity of the device and/or device failure which, in turn, may result in patient injury, illness or death. Creating a risk of

device contamination and/or patient infection or cross-infection, including, but not limited to, the transmission of infectious

disease(s) from one patient to another. Contamination of the device may lead to patient injury, illness or death. Do not exceed the

Rated Burst Pressure (RBP) recommended for this device. Balloon rupture may occur if the RBP rating is exceeded. To prevent over-

pressurization, use of a pressure monitoring device is recommended. Use the recommended balloon inflation medium of contrast

and sterile saline (< 50% contrast). Never use air or any gaseous medium to inflate the balloon. This product should not be used in

patients with known hypersensitivity to paclitaxel or structurally related compounds. The safety and effectiveness of the

Lutonix

Catheter have not been established for treatment in cerebral, carotid, coronary, or renal vasculature. The safety and

effectiveness of using more than two Lutonix drug coated balloons (i.e., a maximum drug coating quantity of approximately 7.6 mg

paclitaxel) in a patient has not been clinically evaluated.

PRECAUTIONS : General Precautions: The LUTONIX

Catheter should only be used by physicians trained in percutaneous interventional

procedures. Consideration should be given to the risks and benefits of use in patients with a history of non-controllable allergies to

contrast agents.

POTENTIAL ADVERSE EVENTS: Potential adverse events which may be associated with a peripheral balloon dilatation procedure include:

Additional intervention, allergic reaction to drugs, excipients or contrast medium, amputation/loss of limb, aneurysm or

pseudoaneurysm, arrythmias, embolization; hematoma; hemorrhage, including bleeding at the puncture site,

hypotension/hypertension, inflammation, occlusion, pain or tenderness, pneumothorax or hemothorax, sepsis/infection, shock,

stroke, thrombosis, vessel dissection, perforation, rupture, or spasm. Although systemic effects are not anticipated, refer to the

Physicians’ Desk Reference for more information on the potential adverse events observed with paclitaxel. Potential adverse events,

not described in the above source, which may be unique to the paclitaxel drug coating include: Allergic/immunologic reaction to the

drug coating (paclitaxel), alopecia, anemia, blood product transfusion, gastrointestinal symptoms, hematologic dyscrasia (including

leukopenia, neutropenia, thrombocytopenia), hepatic enzyme changes, histologic changes in vessel wall, including inflammation,

cellular damage, or necrosis, myalgia/arthralgia, myelosuppression and peripheral neuropathy.

Bard, Advancing Lives and the Delivery of HealthCare and Lutonix are trademarks and/or registered trademarks of C. R. Bard, Inc., or an

Please consult product labels and instructions for use for indications, contraindications, hazards, warnings and precautions. RX Only.


	(d)	Exhibits.

Exhibit		Description
	99.1	Presentation by Patrick Geraghty, MD, FACS, entitled, Clinical Design of the FIRST and ONLY Approved IDE BTK Trial for a Drug Coated Balloon

	99.2	Presentation by Chad Laurich, MD, entitled, Lutonix Global Real World SFA Registry - Interim Results & First Look at LEVANT 2 24 Month Results


Exhibit 99.1		Presentation by Patrick Geraghty, MD, FACS, entitled, Clinical Design of the FIRST and ONLY Approved IDE BTK Trial for a Drug Coated Balloon

Exhibit 99.2		Presentation by Chad Laurich, MD, entitled, Lutonix Global Real World SFA Registry - Interim Results & First Look at LEVANT 2 24 Month Results